SUGT1-DT

Across TCGA pan-cancer cohorts, SUGT1-DT RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SUGT1-DT’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SUGT1-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SUGT1-DT is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

BLCA, COAD, and HNSC are the cancer types where SUGT1-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SUGT1-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	+1.008	<.001	11	view →
COAD	Male	II,III,IV	+1.243	<.001	10	view →
HNSC	All	IV	+0.551	<.001	10	view →
LIHC	Female	II,III,IV	+0.560	<.001	9	view →
STAD	All	II,III,IV	+0.770	<.001	7	view →
UCEC	All	II,III,IV	+0.840	.003	6	view →
KICH	All	All	−0.676	<.001	5	view →
LUSC	Male	All	+0.547	<.001	4	view →
CHOL	All	All	+1.815	<.001	3	view →
READ	Female	All	+1.698	<.001	3	view →
ESCA	All	All	+0.686	.002	2	view →
LUAD	All	All	+0.358	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SUGT1-DT–BLCA

Open the BLCA breakdown →